Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone M Goldinger

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Current Opinion in Oncology|January 7, 2017
A review of serious adverse effects under treatment with checkpoint inhibitorsLucie Heinzerling, Simone M Goldinger
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Adjuvant Therapy in High-Risk Stage III Cutaneous MelanomaFabrice Kaufmann, Simone M Goldinger
Current Opinion in Oncology|January 26, 2016
Treatment of melanoma brain metastasesSimone M Goldinger, Cédric Panje, Paul Nathan
The New England Journal of Medicine|February 3, 2012
Ultraviolet A and photosensitivity during vemurafenib therapyReinhard Dummer, Jeannine Rinderknecht, Simone M Goldinger
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutationsSimone M Goldinger, Carla Murer, Pascale Stieger, et al.
Therapeutische Umschau. Revue Therapeutique|September 1, 2010
[Current therapy of carcinoma of the skin]Reinhard Dummer, Simone M Goldinger, Eva Sailer, et al.
Current Opinion in Oncology|February 4, 2015
Curing advanced melanoma by 2025Reinhard Dummer, Simone M Goldinger, Verena Paulitschke, et al.
Melanoma Research|April 27, 2016
Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activationBenjamin Henning, Pascale Stieger, Jivko Kamarachev, et al.
Melanoma Research|June 2, 2017
Interstitial granulomatous dermatitis during talimogen laherparepvec treatmentAnna L Frauchiger, Marie-Charlotte Brüggen, Simone M Goldinger, et al.
Chemical Immunology and Allergy|May 23, 2012
Cutaneous drug eruptions associated with the use of new oncological drugsBenedetta Belloni, Nicola Schönewolf, Sima Rozati, et al.
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Current Opinion in Oncology|January 7, 2017
A review of serious adverse effects under treatment with checkpoint inhibitorsLucie Heinzerling, Simone M Goldinger
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Adjuvant Therapy in High-Risk Stage III Cutaneous MelanomaFabrice Kaufmann, Simone M Goldinger
Current Opinion in Oncology|January 26, 2016
Treatment of melanoma brain metastasesSimone M Goldinger, Cédric Panje, Paul Nathan
The New England Journal of Medicine|February 3, 2012
Ultraviolet A and photosensitivity during vemurafenib therapyReinhard Dummer, Jeannine Rinderknecht, Simone M Goldinger
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|July 29, 2015
Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutationsSimone M Goldinger, Carla Murer, Pascale Stieger, et al.
Therapeutische Umschau. Revue Therapeutique|September 1, 2010
[Current therapy of carcinoma of the skin]Reinhard Dummer, Simone M Goldinger, Eva Sailer, et al.
Current Opinion in Oncology|February 4, 2015
Curing advanced melanoma by 2025Reinhard Dummer, Simone M Goldinger, Verena Paulitschke, et al.
Melanoma Research|April 27, 2016
Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activationBenjamin Henning, Pascale Stieger, Jivko Kamarachev, et al.
Melanoma Research|June 2, 2017
Interstitial granulomatous dermatitis during talimogen laherparepvec treatmentAnna L Frauchiger, Marie-Charlotte Brüggen, Simone M Goldinger, et al.
Chemical Immunology and Allergy|May 23, 2012
Cutaneous drug eruptions associated with the use of new oncological drugsBenedetta Belloni, Nicola Schönewolf, Sima Rozati, et al.
Pageof 7